Stem Cell Therapy Market Outlook, Industry Analysis Report With BioTime, Osiris Therapeutics, Astellas Pharma, Pluristem Therapeutics, Caladrius Biosciences, Geron Corporation, STEMCELL Technologies, Cytori Therapeutics Inc, Vericel Corporation

The market research report provides up-to-date stem cell therapy’s market information which could assist readers with hands-on information expected to settle on brisk choices anytime during their development venture in the market. The report offers stem cell therapy market presentation, major overview, goals, market definition, extension, and market size estimation. A definite clarification of market values, potential buyers and the future degree are exhibited in this report. This stem cell therapy report incorporates driving variables and opportunities prevailing in this stem cell therapy market, which concentrates the present measurements to broaden the industries quickly. Barriers and limitations of organizations are additionally explained in this report.

Global stem cell therapy market is expected to reach USD 15.63 billion by 2025, from USD 7.72 billion in 2017 growing at a CAGR of 9.2% during the forecast period of 2018 to 2025. The Stem Cell Therapy market report contains data for historic year 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Get Sample of This Research Report: https://databridgemarketresearch.com/request-a-sample/?dbmr=global-stem-cell-therapy-market

Stem cell therapy is the therapy which uses stem cells for the treatment or prevention of a disease. Bone marrow transplant is the widely applicable therapy which is followed by umbilical cord blood. Research is going on to develop various sources (such as cord blood cells, bone marrow and skin) to use these cells for treatment of various disorders like neurodegenerative diseases and conditions such as heart disease, diabetes and other conditions. Some of the major players operating in the global stem cell therapy market are

· Osiris Therapeutics, Inc. (U.S.)

· MEDIPOST Co., Ltd. (South Korea)

· Anterogen Co., Ltd. (South Korea)

· Pharmicell Co., Ltd. (South Korea)

· STEMCELL Technologies Inc.

· Astellas Pharma Inc.

· Cellular Engineering Technologies Inc.

· BioTime Inc.

· Takara Bio Inc.

· U.S. Stem Cell, Inc.

· BrainStorm Cell Therapeutics Inc.

· Caladrius Biosciences, Inc.

· Athersys.

· Cytori Therapeutics, Inc.

· Fate Therapeutics Inc.

· Geron Corporation.

· Pluristem Therapeutics Inc.

· Thermo Fisher Scientific.

· Vericel Corporation.

Others: ViaCyte, Inc, AbbVie, Mesoblast Ltd., Roslin Cells, Regeneus Ltd, ReNeuron Group plc,, International Stem Cell Corporation, Aastrom Biosciences, Inc., Advanced Cell Technology, Cryo Cell International, Cytori Therapeutics, Inc., Geron Corporation, and Invitrogen and others.



Major Market Drivers and Restraints:

Drivers:

· As per growing awareness to therapeutic potency of stem cells in disease organization.

· Because of advanced genome-based cell analysis techniques.

· Due to the increase in the growth rate of public-private investments for stem cell research.

· Because of identification of new stem cell lines.

· Due to the developments in infrastructure for stem cell banking.

Restraints:

· Because of complication associated with preservation of stem cell.

· Difficulty while collecting adult stem cell or somatic stem cells.



The global stem cell therapy market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of the global stem cell therapy market for global, Europe, North America, Asia Pacific and South America.



Get TOC For Full Analysis Of Report: https://databridgemarketresearch.com/toc/?dbmr=global-stem-cell-therapy-market



Segmentation:

The global stem cell therapy market is segmented based on

· Type

· Product

· Application

· End Users

· Geographical Segments

· On the basis of type, the market is segmented into

Allogeneic stem cell therapy
Autologous stem cell therapy
· The allogeneic stem cell therapy segment is expected lead the market because of commercialization of allogeneic stem cell therapy products and wide application with easy scale up process.

· Based on products, the market is segmented into

Adult stem cells
Human embryonic stem cells
Induced pluripotent stem cells and others
· The adult stem cells accounts highest share in market due to ability to generate trillions of specialized cells which may lower the risks of rejection and repair tissue damage.

· Based on application, the market is segmented into

Musculoskeletal disorders
Wounds and injuries
Cardiovascular diseases
Surgeries
Gastrointestinal diseases, and other applications
· The musculoskeletal disorders segment leads the market due to availability of stem cell-based products for the treatment of musculoskeletal disorders, high prevalence of musculoskeletal disorders and bone & joint diseases.

· Based on end users, the market is segmented into

Therapeutic companies
Cell and tissues banks
Tools and reagent companies
Service companies
· The growing number of stem cell donors, improved stem cell banking facilities and because of the research and development therapeutic companies held the largest share in stem cell therapy.

· Based on geography ,the market report covers data points for 28 countries across multiple geographies namely

· North America & South America

· Europe

· Asia-Pacific

· Middle East & Africa

· Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and Brazil among others.



Potential held by the report

· In March 2016, Scientists at Michigan State University unveiled new kind of cells “induced XEN cells” from a cellular trash pile. This discovery is expected to drive advancements in regenerative medicine.

· On February 13, 2018- Astellas Pharma Inc. (Japan) and Universal Cells, Inc. (Japan) announced that Astellas has assimilated with Universal Cells. Astellas would gain Universal Cells’ proprietary Universal Donor Cell technology to create cell therapy products that do not require Human Leukocyte Antigen (HLA) matching, potentially overcoming a huge treatment challenge by reducing the risk of rejection.

· In October 2017, the Astellas Institute for Regenerative Medicine (AIRM) and Universal Cells entered into an exclusive license agreement to utilize Universal Donor Cell technology in a single indication.



Want Full Report? Enquire Here: https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-stem-cell-therapy-market

Related Report:

Global Cell Harvesting Market is expected to reach USD 387.9 Million by 2025, from USD 196.9 Million in 2017 growing at a CAGR of 8.9% during the forecast period of 2018 to 2025. The market report contains data for historic years 2017, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Visit: https://databridgemarketresearch.com/reports/global-cell-harvesting-market/

Contact Us

Data Bridge Market Research
Toll Free: +1-888-387-2818
Mail: sopan.gedam@databridgemarketresearch.com
http://databridgemarketresearch.com

About Us

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing sopan.gedam@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.

This release was published on openPR.